カガム　ヒロシ   KAGAMU Hiroshi   各務　博    所属   埼玉医科大学  医学部 国際医療センター　呼吸器内科    職種   教授
論文種別	学術雑誌(原著)
言語種別	英語
査読の有無	査読あり
表題	Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset.
掲載誌名	正式名：Japanese Journal of Clinical Oncology ISSNコード：03682811
掲載区分	国内
巻・号・頁	48(4),367-375頁
著者・共著者	Kiura, K. Imamura, F. Kagamu, H. Matsumoto, S. Hida, T. Nakagawa, K. Satouchi, M. Okamoto, I. Takenoyama, M. Fujisaka, Y. Kurata, T. Ito, M. Tokushige, K. Hatano, B. Nishio, M.
発行年月	2018/04
概要	Among the 231 patients, 29 were Japanese, of which, 11 were treated with ceritinib and 18 were treated with chemotherapy (5 with pemetrexed and 13 with docetaxel). All the patients received prior crizotinib and one or two lines of prior chemotherapy for advanced disease. Median follow-up time was 16.6 months for ceritinib arm and 16.4 months for chemotherapy arm in the overall population. The median PFS by blinded independent review committee was 9.8 months (95% CI, 4.3-14.0) in ceritinib arm vs 1.6 months (95% CI, 1.4-3.0) in chemotherapy arm. Conclusions: Consistent with overall population, ceritinib demonstrated better efficacy compared with the standard second-line chemotherapy in Japanese patients with crizotinib-resistant ALK+ NSCLC. ClinicalTrials.gov identifier: NCT01828112.